USP7 or HAUSP is a ubiquitin specific protease in human cells that regulates the turnover of p53 and is bound by at least two viral proteins, the ICP0 protein of herpes simplex type 1 and the EBNA1 protein of Epstein-Barr virus. We have overexpressed and purified USP7 and shown that the purified protein is monomeric and is active for cleaving both a linear ubiquitin substrate and conjugated ubiquitin on EBNA1. Using partial proteolysis of USP7 coupled with MALDI-ToF mass spectrometry, we showed that USP7 is comprised of four structural domains; an N-terminal domain known to bind p53, a catalytic domain and two C-terminal domains. By passing a mixture of USP7 domains over EBNA1 and ICP0 affinity columns, we showed that the N-terminal p53 binding domain was also responsible for the EBNA1 interaction, while the ICP0 binding domain mapped to a C-terminal domain between amino acids 599 to 801. Tryptophan fluorescence assays showed that an EBNA1 peptide mapping to residues 395-450 was sufficient to bind the USP7 N-terminal domain and did so with a dissociation constant of 0.9 to 2 µM, whereas p53 peptides spanning the USP7-binding region gave dissociation constants of 9 to 17 µM in the same assay. In keeping with these relative affinities, gel filtration analyses of the complexes showed that the EBNA1 peptide efficiently competed with the p53 peptide for USP7 binding, suggesting that EBNA1 could affect p53 function in vivo by competing for USP7.
Summary
USP7 or HAUSP is a ubiquitin specific protease in human cells that regulates the turnover of p53 and is bound by at least two viral proteins, the ICP0 protein of herpes simplex type 1 and the EBNA1 protein of Epstein-Barr virus. We have overexpressed and purified USP7 and shown that the purified protein is monomeric and is active for cleaving both a linear ubiquitin substrate and conjugated ubiquitin on EBNA1. Using partial proteolysis of USP7 coupled with MALDI-ToF mass spectrometry, we showed that USP7 is comprised of four structural domains; an N-terminal domain known to bind p53, a catalytic domain and two C-terminal domains. By passing a mixture of USP7 domains over EBNA1 and ICP0 affinity columns, we showed that the N-terminal p53 binding domain was also responsible for the EBNA1 interaction, while the ICP0 binding domain mapped to a C-terminal domain between amino acids 599 to 801. Tryptophan fluorescence assays showed that an EBNA1 peptide mapping to residues 395-450 was sufficient to bind the USP7 N-terminal domain and did so with a dissociation constant of 0.9 to 2 µM, whereas p53 peptides spanning the USP7-binding region gave dissociation constants of 9 to 17 µM in the same assay. In keeping with these relative affinities, gel filtration analyses of the complexes showed that the EBNA1 peptide efficiently competed with the p53 peptide for USP7 binding, suggesting that EBNA1 could affect p53 function in vivo by competing for USP7.
Introduction
The modification of proteins by the addition of ubiquitin controls a wide variety of cellular processes in eukaryotes. Formation of branched polyubiquitin chains on the ε amino group of select lysines in a target protein directs the protein for degradation by the 26S proteasome, and this system of selective protein degradation plays an integral role in many cellular processes, such as cell cycle progression, signal transduction, differentiation, and chromosome segregation (reviewed in (1) (2) (3) (4) (5) ). Important biological effects can also be incurred by the addition of single ubiquitin moieties to proteins, a modification that regulates protein function without targeting the protein for proteasomal degradation (reviewed in (6, 7) ).
Both poly-and monoubiquitination can be reversed by deubiquitinating enzymes (DUBs) that specifically cleave the isopeptidic bond at the C terminus of ubiquitin. DUBs also generate the pool of free ubiquitin both by liberating ubiquitin from precursor ubiquitin-fusion proteins and by recycling ubiquitin from the branched polyubiquitin chains of degraded proteins (reviewed in (8) (9) (10) ). The DUBs are comprised of two groups of enzymes, the UCHs (Ubiquitin C-terminal Hydrolyases) and the USPs (Ubiquitin Specific Processing Proteases; referred to as UBPs in yeast). The UCHs are small, closely related proteases (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) size) that are generally involved in cleaving ubiquitin from small processed peptides. The USPs are more numerous, much larger in size (60-300 kDa) and are thought to have specific protein targets. USPs can be identified by conserved sequences within the active site, but sequences outside of the catalytic domain are highly divergent, likely reflecting their role in mediating interactions with different protein targets (10) (11) (12) . There are 16 
known UBPs in
Saccharomyces cerevisiae, and 63 putative USP genes in humans (8) . Single and even multiple UBP deletions in yeast generally produce minimal phenotypic abnormalities, suggestive of functional redundancies among the yeast UBP family (13) . However, studies have shown that USPs can play specific roles in various biological processes in higher eukaryotes, suggesting a more specialized role as cellular regulators in multicellular organisms.
Specific DUBs have been shown to regulate eye development (14, 15) , cell growth in response to cytokines (16) , oncogenic transformation (17) (18) (19) , cell cycle regulation (11) , chromatin structure (7) and transcriptional regulation (20, 21) .
The human DUB called USP7 or HAUSP (Herpes Associated Ubiquitin Specific Protease), was first identified by virtue of its interaction with the herpes simplex virus type I immediate early protein, ICP0 (also called Vmw110) (22, 23) . ICP0 is an E3 ubiquitin ligase (24) that is important for induction of the lytic infectious cycle. ICP0 promiscuously activates gene expression (25) and induces the destruction of some cellular proteins, including those of kinetochores (26) and ND10 nuclear structures (27) .
USP7 binds ICP0 through the C-terminal portion of ICP0, which is important for activating gene expression, and the ability of USP7 to bind ICP0 correlates with the ability of ICP0 to activate gene expression, suggesting a role for USP7 in this process (28) .
USP7 is also the target of another herpes virus protein, namely the EBNA1 protein of Epstein-Barr virus (EBV) (29) . EBNA1 binds to the latent origin of DNA replication and governs the replication and segregation of the EBV episomes during latent infection (30, 31) . EBNA1 also activates the expression of other viral latency genes and is implicated in the immortalization of host cells by EBV (32, 33) . EBNA1 is thought to contribute to these processes through specific interactions with host cellular proteins. Recently, we used both an in vitro affinity column approach and an in vivo tandem affinity purification (TAP-tagging) approach to profile cellular protein interactions with EBNA1, and identified USP7 as specifically interacting with EBNA1 in both assays (29) . USP7 and EBNA1 were also found to interact when co-expressed in insect cells, indicating that no additional human proteins are required for this interaction.
This interaction was selectively disrupted by deletion of EBNA1 residues 395-450, just upstream of the DNA binding domain, and the resulting EBNA1 mutant had increased DNA replication activity, suggesting that USP7 can influence the efficiency of EBV replication from the latent origin.
Insight into the cellular function of USP7 came from a recent study by Li et al (34) , who showed that USP7 regulated the turnover of p53. USP7 was isolated on a p53 affinity column and subsequently shown to co-immunoprecipitate with p53.
Overexpression of USP7 stabilized p53 and induced p53-dependent growth repression and apoptosis. These effects were likely due to deubiquitination of p53 by USP7, since the over expression of USP7 resulted in increased levels of deubiquitinated p53, and since dominant negative effects on p53 levels and ubiquitination were observed using a catalytically inactive USP7 point mutant. A role for USP7 in apoptosis was also supported by a study by Vugmeyster et al (35) , who reported the caspase-dependent proteolysis of USP7 during apoptosis in thymocytes. The p53-USP7 interaction was shown to involve the N-terminal portion of USP7 and the C-terminal regulatory region of p53 (11) . This N-terminal region of USP7 contains a TRAF domain (tumour necrosis
The interaction of viral proteins with USP7 suggests that some viruses may influence cellular events by sequestering or altering the activity of USP7. We have begun to explore this possibility by defining the domain structure of USP7 and determining which domains are bound by EBNA1 and ICP0. Here we show that EBNA1 binds the N-terminal USP7 domain with 10-fold higher affinity than p53, effectively competing with p53 for USP7, while ICP0 binds a C-terminal domain.
Experimental Procedures

Expression and purification of USP7
A USP7 baculovirus was constructed using full length USP7 cDNA (kindly provided by R. Everett) in a pET-3a vector. The cDNA was excised with NdeI and HindIII, and cloned into the same sites of pET-15b (Novagen), downstream of the hexahistidine tag. N terminally tagged USP7 was excised from pET-15b using XbaI and HindIII, and cloned between the XbaI and HindIII sites of the pFastBac vector (GIBCO). Bacmid DNA was prepared and used to transfect Spodoptera frugiperda (Sf9) insect cells to generate baculovirus according to manufacturer's specifications. Culture medium containing the baculovirus was harvested 5 days post-transfection and amplified once.
Hi5 insect cells were seeded into 27 150 cm 2 culture flasks at 5 X 10 6 cells per flask, and g for 30 minutes at 4 ° C, before loading onto a 4 ml Talon cobalt column (Clontech).
After washing extensively with buffer A (50 mMNaH 2 PO 4 , pH 7.0, 300 mM NaCl, 10% glycerol, 5 mM imidazole,), tagged USP7 was eluted from the column using 15 ml of buffer A containing 150 mM imidazole. Pertinent fractions were pooled and dialyzed overnight against 20 mM Tris-HCl, pH 7.6, 200 mM NaCl, 1 mM 1,4-dithiothreitol (DTT), 1 mM ethylenediaminetetraacetic acid (EDTA), and 5% glycerol. 
Analytical Centrifugation
Sedimentation equilibrium analyses were performed at the Ontario Cancer Institute in the laboratory of Avi Chakrabartty, on a Beckman XLI Analytical Ultracentrifuge using an AN50-Ti rotor and sapphire windows. Sedimentation experiments, using six-channel charcoal-Epon cells, were performed at 20 o C using three different concentrations of purified USP7 (0.32, 0.63 and 1.3 mg/ml) in 50 mM NaH 2 PO 4 ,pH 7.5, 50 mM NaCl, 1 mM EDTA, 10 % glycerol, 1 mM Tris(2-carboxyethyl) phosphine-HCl (TCEP).
Centrifugation was carried out at three different speeds (16,000, 17,500 and 19,000 rpm)
for 30 hours to ensure that equilibrium was reached before absorbance measurements were taken. Data were analyzed using Beckman XL-A/XL-I software version 4.0.
Purification of GST-Ub52
BL21(DE3)pLysS cells were transformed with pGEX2T-Ub52 (kindly provided by R.
Everett; (23)) and expression of GST-Ub52 was induced by addition of 0.1 mM IPTG at 37° C for two hours. Cells were lysed by sonication in NETN buffer (20 mM Tris-HCl, pH 7.9, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40, 1 mM PMSF), and the lysate was clarified by centrifugation for 15 minutes in an SS34 Sorvall rotor at 15,000 rpm at 4°C.
The supernatant was incubated for 2 hours at 4°C with 0.5 ml glutathione sepharose beads (Amersham Pharmacia) equilibrated in NETN plus 0.5% milk powder. The glutathione sepharose beads were washed extensively with NETN, and once with 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 12 mM MgCl 2 , before eluting in 100 mM Tris-HCl, pH 8.0, 120 mM NaCl, 20 mM reduced glutathione. The eluate was dialyzed overnight against 20 mM Tris-HCl, pH 7.6, 50 mM NaCl, 0.5 mM DTT.
Linear substrate cleavage assays
Purified USP7 and GST-Ub52 were preincubated separately for 10 minutes on ice (USP7) or at room temperature (GST-Ub52) in reaction buffer (20 mM Tris-HCl, 10 mM DTT unless otherwise noted), prior to combining the two proteins. For cleavage reactions, 3.6 nM USP7 was incubated with 3.6 µM GST-Ub52 in reaction buffer at 37°
C. 20 µl aliquots containing 3 µg GST-Ub52 were withdrawn at the indicated times, 
Ubiquitination and Deubiquitination of EBNA1
5 µg of purified EBNA1 was ubiquitinated at room temperature in the following: 66% rabbit reticulocyte lysate (Promega), 1.5 µg ubiquitin (Sigma), 260 µM ALLN (Sigma), 50 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 1 mM DTT, 1 mM ATP, 10 mM creatine phosphate, 0.1 mg/ml creatine phosphokinase, 100 mM NaCl. Aliquots were taken just before and at 1, 15, 30, and 60 minutes after addition of EBNA1. After 60 minutes, 1.4
µg of purified USP7 was added to the remaining 3 µg of ubiquitinated EBNA1, and aliquots were removed at 60 and 120 minutes after the addition of USP7. Reactions were terminated by adding SDS-PAGE loading buffer (containing 2% SDS and 6 M urea).
Proteins were separated by 10% SDS-PAGE, Western blotted and probed with K67 anti-EBNA1 antisera (kindly provided by J. Middledorp).
Partial Proteolysis of USP7
Purified USP7 was partially digested with either trypsin or chymotrypsin at a ratio of 1:100 or 1:50, respectively, for 2 hours at 37 ° C in 50 mM HEPES, pH 7.8, 50 mM NaCl, 5 % glycerol, and 1 mM DTT. Reactions were stopped either by addition of SDS-PAG loading buffer (for separating fragments by SDS-PAGE) or by addition of 2X complete protease inhibitor (Roche) and placing on ice until loading onto the affinity columns. Protein bands in SDS-PAG were excised and identified by complete tryptic digestion, followed by identification of the tryptic peptides by MALDI-ToF mass spectrometry as previously described (29), using PAWS or ProFound software (Proteometrics).
EBNA1 Affinity columns
EBNA1 (lacking most of the Gly Ala repeat region) was expressed in insect cells with an N-terminal hexahistidine tag and purified as previously described (29) . Purified EBNA1 was coupled to Affigel-10 at a concentration of 1 mg EBNA1/ml resin as described in
Holowaty et al (29) . 25 µl affinity columns were equilibrated in buffer C (20 mM TrisHCl, pH 7.6, 0.2 M NaCl) before addition of 64 µg of the partially proteolyzed USP7 or an equimolar mixture of individually-expressed and purified USP7 fragments (400 pmol each fragment). Columns were washed with 8 column volumes buffer C, and bound polypeptides were eluted by increasing the NaCl concentration to 1 M and subsequently by the addition of 1% SDS (to buffer C). Column fractions were analyzed by SDS-PAGE and Coomassie staining.
ICP0 Affinity Columns
Amino acids 594 to 775 of ICP0 of HSV-1 was expressed as a GST-fusion in BL21(DE3)pLysS cells from pGEX-E52 (kindly provided by R. Everett; (22)). After a 4
hour induction at room temperature with 0.1 mM IPTG, cells from 25 ml of culture were lysed by sonication in PBS plus 0.5 % Triton X-100 and complete protease inhibitors (Roche). After clarification of the lysate by centrifugation, the supernatant was incubated with 100 µl of glutathione sepharose beads (Amersham Pharmacia) overnight at 4°C.
The beads were washed 3 times with PBS, twice with PBS containing 300 mM NaCl, and twice more with PBS, before being resuspended in PBS. 25 µl columns were generated from the ICP0-bound beads, and these were equilibrated in buffer C and used to assess binding of partially proteolysed USP7 fragments as described for EBNA1 affinity columns.
Generation of EBNA1 peptide
An EBNA1 fragment coding for amino acids 395 to 450 was PCR amplified and cloned between the NdeI and BamHI sites of pET15b (Novagen), downstream of the hexahistidine tag. The EBNA1 peptide was expressed at 25°C in BL21(DE3)pLysS cells after a 4 hour induction with 0.5 mM IPTG. Cells were lysed by sonication in buffer D (20 mM Tris-HCl, pH 7.9, 500 mM NaCl, 1 % Triton X-100, 5 mM imidazole, and complete protease inhibitor (Roche)) and the lysate was clarified by centrifugation for 30 minutes in an SS34 Sorvall rotor at 15, 000 rpm. The supernatant was incubated with
Talon cobalt resin (Clontech) overnight at 4° C and, after extensive washing with buffer D lacking detergent, the peptide was eluted with buffer D containing 250 mM imidazole.
The eluted EBNA1 peptide was dialyzed against buffer C, then further purified by passing through a 50 K molecular weight cut off centricon filter (Millipore). The concentration of the peptide was determined by OD280.
Generation of p53 peptide
Human p53 fragments encoding amino acids 311 to 393 and 355 to 393 were cloned between the NdeI and BamHI sites of pET15b downstream of a hexhistidine tag. p53
proteins were overexpressed in BL21-CodonPlus E.coli (Stratagene) upon addition of 1mM IPTG. Three hours after induction at 25 °C, cells were lysed by sonication in buffer D and the tagged peptides were purified from the clarified lysate on Talon cobalt columns as described for the EBNA1 peptide. After concentration by ultracentrifugation in a centricon with a 5K molecular weight cut off, the concentration of the p53 311-393 peptide was determined by OD280 and the concentration of the p53 355-393 peptide (which lacks aromatic residues) was measured by comparing with protein standards on a SDS-PAGE gel.
Tryptophan Fluorescence Assay
Fluorescence measurements were performed in an Aviv ATF105 ratio spectrofluorometer. Peptide binding titrations were performed by stepwise mixing of the target peptide (monomeric p53 355-393, tetrameric p53 311-393, or EBNA1 395-450)
with the USP7 1-205 fragment, using a Microlab 500 series automated titrator. Binding reactions contained 1 µM USP7 in 2 ml of 20 mM Tris, pH 7.6, 200 mM NaCl. After mixing, the samples were incubated for 1 minute at room temperature, and the degree of binding was assessed by measuring the total tryptophan fluorescence at 350 nm, using an excitation wavelength of 295 nm. The change in fluorescence signal was plotted as a function of target peptide concentration, and fit to the following equation as described in
Maxwell and Davidson (37), using Kaleidograph software to determine the K d values:
(I∞ -I 0 ) + I 0 (38) .
Assessment of protein interactions by gel filtration
The 
RESULTS
Purification and biochemical characterization of USP7. Full-length USP7 was expressed as a hexahistidine fusion in insect cells from a baculovirus. Whole cell lysates showed that fulllength USP7 (130 kDa) was expressed at high levels in a soluble form ( Figure 1A ). The tagged USP7 was purified on a metal chelating column yielding approximately 9 mg of purified USP7 from 1.3 x 10 8 insect cells ( Figure 1A ). To determine if the purified recombinant USP7 was catalytically active, we tested its ability to cleave a linear ubiquitin fusion protein, GST-Ub52, which was previously shown to be cleaved by USP7 when the two proteins were expressed in E.coli (23) . Purified USP7 was combined with purified GST-Ub52 at an enzyme:substrate molar ratio of 1:1000, and the cleavage of the ubiquitin moiety within GST-Ub52 was monitored over time by SDS-PAGE, followed by SYPRO-orange protein staining. As shown in Figure 1B , USP7 efficiently cleaved GST-Ub52 under these conditions, cleaving 50% of the substrate in approximately 2 minutes.
Since in vivo USP7 is thought to cleave conjugated (as opposed to linear) ubiquitin chains, we also tested the ability of the purified USP7 to cleave conjugated ubiquitin chains.
These were generated on the Epstein-Barr virus EBNA1 protein, which is known to bind USP7
and therefore likely to be a target of the deubiquitination activity. Purified EBNA1 was ubiquitinated by incubation with ubiquitin in a rabbit reticulocyte lysate, which contains ubiquitin conjugating enzymes, and the resulting EBNA1 species were detected by Western blotting using an EBNA1 antibody. As shown in Figure 1C (lanes 2-5), EBNA1 was quickly converted to a ladder of higher molecular weight conjugates, typical of a heterogenously ubiquitinated protein. After incubation with purified USP7, the high molecular weight EBNA1
conjugates were reduced to the position of EBNA1 alone (lanes 6 and 7). Western blot of the lysate lacking EBNA1 showed that the EBNA1 antibody did not cross-react with proteins in the lysate (lane 1). We have also purified the EBNA1 conjugates after the ubiquitination reaction (by virute of a histidine tag on EBNA1) and shown that the conjugates are recognized by anti-ubiquitin antibodies (data not shown). The results indicate that EBNA1 can be efficiently ubiquitinated in vitro and can be deubiquitinated by the purified USP7.
Since the linear ubiquitin cleavage assay could be easily quantified, we used it to define the sensitivity of the catalytic activity of purified USP7 to various salt concentrations, divalent cations, pH and protease inhibitors. Time courses of GST-Ub52 cleavage were performed multiple times and average values are shown in Figure 2 . USP7 cleaved GST-Ub52 at a similar rate in NaCl concentrations up to 120 mM, but this cleavage rate sharply decreased when the NaCl concentration was increased to 195 mM and higher ( Figure 2A and Table 1 ).
However, USP7 remains partially active even at 520 mM NaCl, as 80 % of the substrate was cleaved in this condition upon overnight incubation with a 1:1000 molar ratio of USP7:GSTUb52 (data not shown). USP7 was also found to be quite tolerant of high pH, as it exhibited complete GST-Ub52 cleavage activity at pHs between 7.0 and 9.5 ( Figure 2C) . A marked decrease in activity was seen at pH 6.2, however. As expected based on studies with other USPs, USP7 catalytic activity was effectively inactivated by the thiol-blocking reagent Nethylmaleimide (NEM) at 1mM, but was not affected by the proteasomal inhibitor, N-acetylleu-leu-norleucinal (ALLN), or the serine protease inhibitor, PMSF, at the same concentration ( Figure 2D ). The inhibition by NEM was reversible, as USP7 activity was restored upon quenching of the NEM with DTT (data not shown).
When the effect of divalent cations on USP7 catalytic activity was examined, the presence of 5 mM MnCl 2 , MgCl 2 , or CaCl 2 was found to decrease the rate of cleavage of GST-Ub52 approximately 3-fold ( Figure 2B and Table 1 ). In keeping with the inhibitory effect of divalent cations on USP7, we also observed a modest stimulation of the rate of substrate cleavage by USP7 in the presence of 1 mM EDTA ( Figure 2B and Table 1 ). The observed effects of metals and metal chelating agents on substrate cleavage by USP7 could be due to effects on the structure of either USP7 itself or the GST-Ub52 substrate. We considered the possibility that the divalent cations might be activating a trace protease contaminant in the USP7 preparation, which could then degrade a proportion of the USP7 during the 10 minute preincubation step, prior to the addition of the GST-Ub52 substrate. This possibility was ruled out by showing that the preincubation of USP7 with 5 mM CaCl 2 did not irreversibly inhibit USP7 activity; wild type activity was restored when 10 mM EDTA was added after preincubation with the divalent cation (data not shown).
Some USPs have been reported to be monomeric while others appear to be dimers (39) (40) (41) , but the native aggregation state of USP7 has not been determined (41) . We investigated the native state of USP7 by analytical centrifugation, analysing three different concentrations of USP7 under conditions in which the enzyme is active. The data indicated that USP7 was homogeneous with an apparent molecular weight of 128,815 Da, which approximates the calculated molecular weight of 130,436 Da for hexahistidine-tagged USP7. Therefore full length USP7 is monomeric under the conditions tested.
Mapping of the protein interaction domains of USP7. USP7 has been shown to bind p53, the ICP0 protein of herpes simplex and the EBNA1 protein of Epstein-Barr virus. While the p53-binding region of USP7 has been mapped to the N-terminus between amino acids 53 to 208 (11), the regions responsible for binding ICP0 and EBNA1 have not been determined. In order to map the protein interaction domains of USP7, we first used partial proteolysis to define the structural domains of USP7. To this end, purified USP7 was incubated with either trypsin or chymotrypsin for increasing amount of time until distinct proteolytic products were observed by SDS-PAGE, that were relatively resistant to further digestion. Such a pattern of bands became evident after a 2 hr incubation with 1:100 mass ratio of trypsin and a 1:50 mass ratio of chymotrypsin, and examples are shown in the "load" lanes in Figures 3A, 3B and 5.
These experiments were performed numerous times and the protease-resistant fragments generated were identified by excising the bands from SDS-PAGE, completely digesting the excised polypeptides with trypsin and identifying the tryptic fragments by MALDI-ToF mass spectrometry. A summary of the protease-resistant USP7 fragments obtained from these experiments is shown in Figure 4 , in relation to the position of the previously mapped catalytic domain (amino acids 208-560; (11)). This method identified two structural domains Cterminal to the catalytic domain, mapping approximately to amino acids 600-870 and amino acids 885-1061. It also showed that the region N-terminal to the catalytic domain consisted of a single structural domain beginning at amino acid 67. The C-terminal edge of this domain was not well defined by protease digestion but likely extends to close to the catalytic domain.
To determine which USP7 domain interacted with EBNA1, purified EBNA1 was coupled to Affigel-10 to generate EBNA1 affinity columns, and partially proteolysed USP7 was applied to the column in buffer containing 200 mM NaCl. After washing the column, the EBNA1-bound USP7 fragments were eluted, first with high salt and then with SDS. Examples of experiments performed with USP7 partially digested with trypsin and with chymotrypsin are shown in Figures 3A and 3B , respectively. Identical experiments were performed using Affigel-10 columns lacking EBNA1 as a negative control. Experiments with the USP7 tryptic fragments consistently showed that the fragments spanning the N-terminal domain of USP7
were preferentially retained on the EBNA1 column, while fragments from the C-terminal region flowed through the column (fragments 599-871 and 900-1050 in Figure 3A ).
Preferential retention of USP7 fragments was not observed on the control column. Similar results were obtained using USP7 chymotryptic fragments; in this case fragments containing the N-terminal domain were retained on the EBNA1 column (fragments 67-322 and 67-254 in Figure 3B ), while fragments containing C-terminal and catalytic sequences flowed through the column (fragments 263-745 and 785-1061 in Figure 3B ). Figure 4 shows all of the USP7 fragments that were retained on the EBNA1 columns from three experiments. The results
show that EBNA1 binding occurs through USP7 sequences located in the N-terminal portion of the protein.
While all of the USP7 proteolysis fragments that bound EBNA1 contained the USP7 Nterminal domain, most of the fragments also contained all or part of the catalytic domain. In order to clarify whether EBNA1 binding occurred through the USP7 N-terminal domain or involved sequences from the catalytic domain, we expressed and purified USP7 fragments containing only the N-terminal domain (1-205 and 56-205), only the catalytic domain (202-580) or both the N-terminal and catalytic domains (1-580). These fragments were combined in equimolar amounts, along with purified full length USP7 (1-1102), and applied to an EBNA1 affinity column ( Figure 3C ). All of the USP7 fragments containing the N-terminal domain were retained on the EBNA column and eluted in high salt, while the catalytic domain flowed through the column. None of the USP7 fragments were retained on negative control columns lacking protein (control) or containing the C-terminal portion of EBNA1 (amino acids 452-641), which contains the DNA binding domain but lacks the USP7 binding region. The results indicate that EBNA1 binds to USP7 through the N-terminal domain located between amino acids 56-205 of USP7, which is the same domain that has been shown to bind p53 (11).
We also used partially proteolysed USP7 to determine which USP7 domain binds the ICP0 protein of herpes simplex. To this end, a fragment of ICP0 (amino acids 594-775) that was previously shown to be sufficient to bind USP7 was expressed as a GST fusion and bound to glutathione sepharose (22) . As shown in Figure 5A , when partially proteolysed USP7 was passed through the ICP0 column, two USP7 fragments, 323-801 and 524-801, were retained on the column and eluted in high salt; fragments containing the N-terminal and catalytic USP7
domains and the second C-terminal domain (amino acids 885-1084) flowed through the column. USP7 fragment were not found to be retained on the negative control column containing GST alone. The analysis of the interaction of USP7 fragments with ICP0 affinity columns was conducted three times and the results are summarized in Figure 5B . The results indicate that ICP0 interacts with a different USP7 domain than that bound by EBNA1 and p53
and that this domain is located between the catalytic domain and amino acid 801.
Comparison of the USP7 binding affinities of EBNA1 and p53. We have previously shown that USP7 binds to EBNA1 but not to an EBNA1 deletion mutant lacking amino acids 395-450, suggesting that the USP7 binding site is between amino acids 395-450. To determine whether this fragment of EBNA1 was sufficient to bind USP7 and to obtain quantitative data on the USP7-EBNA1 interaction, we used a tryptophan fluorescence assay. USP7 fragment 1-205, containing the N terminal domain shown to bind to both EBNA1 and p53, encodes 6 tryptophan residues. An EBNA1 peptide containing amino acids 395-450 (and lacking tryptophan residues) was expressed as a hexahistidine fusion, purified and titrated with the A representative experiment is shown in Figure 6A . Dissociation constants calculated from 2 separate experiments were 0.88 and 2.07 µM, indicating that EBNA1 residues 395-450 are sufficient to bind USP7 with high affinity.
To determine how the affinity of USP7 for EBNA1 compares to that for p53, we repeated the tryptophan fluorescence binding assay with the USP7 1-205 fragment and a p53
peptide (amino acids 355-393) that contains the sequences previously shown to be sufficient to bind USP7 (11) and that lacks tryptophan residues. As shown in the titration in Figure 6B ( Figure 7F ). Displacement of all detectable p53 peptide from USP7 was observed when the amount of EBNA1 peptide added was increased to a 3-fold molar excess ( Figure 7G ).
In contrast, the complex formed between the EBNA1 peptide and USP7 ( Figure 7E ) was not disrupted by addition of equal molar amounts of the p53 peptide ( Figure 7F ).
Therefore the results show that EBNA1 can effectively compete with p53 for USP7
binding.
Discussion
It is becoming increasingly clear that deubiquitinating enzymes play important roles in a variety of cellular processes, yet to date few have been purified and characterized. We have purified USP7 and shown it to be active for cleavage of linear and conjugated ubiquitin, as well as for interactions with known protein targets. The efficiency with which USP7 cleaves linear ubiquitin in vitro (50% cleaved in 2 minutes with a 1:1000 ratio of enzyme to substrate) compares very favourably to that reported for other purified USPs. For example, incubation of human USP5 (formerly known as isopeptidase T) with a head to tail dimer of ubiquitin at a 1:120 molar ratio resulted in only 50% cleavage of the substrate in 20 minutes (39) . Similarly, approximately 50% of Ub-CEP80, Ub-DHFR or Ub-PESTc substrates were cleaved by chick UCH-8 (thought to be a UBP despite its name) in 2 hours at an enzyme:substrate ratio of 1:100 (40) . Purified S. cerevisiae UBP6 and human USP10 were even less active; UBP6 cleaved 50% of the Ub-CEP80 or Ub-DHFR substrates after a 2 hour incubation at a 1:1 molar ratio (41), and 50% cleavage of a linear ubiquitin hexamer by USP10 required approximately a 30 minute incubation at a 1:1 molar ratio (42).
USP7 is quite tolerant to high salt conditions and pH variation, with complete activity seen at pH 7-9.5. In comparison, UCH-8 (40) and UBP6 (41) showed a more restricted activity range peaking at pH 7.5-8.0 and pH 8.5-9.0, respectively. USP7 was also found to be approximately 6-fold more active for cleaving the linear substrate in the presence of EDTA as compared to in the presence of 5 mM divalent cations. Presently it is not clear whether this result is due to effects on the structure of the substrate, since part of the Ub52 fusion protein contains a zinc finger, or on the enzyme itself. Two lines of evidence suggest that the effects may occur through change to the catalytic domain. First, similar inhibitory effects of divalent cations have been reported for UCH-8, which was inhibited 2-3 fold by 5 mM Ca 2+ or Mg
2+
and inhibited 50-fold by 5mM Mn 2+ (40) . Second, the crystal structure of the catalytic domain of USP7 was recently determined in isolation and in complex with ubiquitin aldehyde and these structures revealed that the active site undergoes a major structural change upon binding of ubiquitin aldehyde, which aligns the catalytic triad for catalysis (11) . The closest structural homologue to this USP7 domain is the µ calpain protease core domain, which undergoes a similar large conformational change when Ca 2+ is bound. Thus there is precedent for divalent cations altering the structure of protein cleavage domains like that of USP7.
We have explored the domain structure of USP7 in order to determine how many sequence identity, but USP7 is also conserved in yeast with 34% and 30% identity in S.
pombe (SpUbp21) and S. cerevisiae (ScUbp15), respectively. The conserved sequence of USP7 suggests that the function of USP7 has been evolutionarily conserved. While it is the catalytic domain that is most highly conserved across species, there is significant sequence conservation throughout most of the N-terminal and C-terminal domains, suggesting the functional importance of these domains. Interestingly, while residues corresponding to the N-terminal protease resistant domain are conserved in mouse (97%, identical), mosquito (48% identical) and fruit fly (44% identical), residues corresponding to the first 58 amino acids of human USP7 are either absent (mouse) or highly divergent, suggesting that they are not critical for function. It is likely that the conserved N-terminal domain can mediate interactions with several different proteins since, in addition to binding p53 and EBNA1, this domain has been shown to bind TRAF proteins in vitro and to be important for getting USP7 into the nucleus (36) .
The fact that EBNA1 and p53 interact with the same USP7 domain, raised the possibility that EBNA1 may interfere with p53 binding to USP7. Since EBNA1 appears to bind this domain 10 times more avidly than p53, it would be expected to efficiently compete with p53 for USP7 binding if the two proteins share the same or overlapping binding sites on USP7. Gel filtration analyses of USP7-p53 and USP7-EBNA1 complexes showed that EBNA1 indeed inhibited the ability of p53 to bind USP7.
EBNA1 binding to USP7, however, was not affected by p53 under the same conditions, likely due to the higher affinity of USP7 for EBNA1. The p53-USP7 interaction has been shown to stabilize p53, thereby inhibiting cell cycle progression and inducing apoptosis (34) . Therefore by disrupting this interaction, EBNA1 would be expected to promote cell cycle progression and prevent apoptosis, which could be important for the host cell 
